Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[
Animals
Brain Neoplasms
/ diagnosis
Carrier Proteins
/ agonists
Disease Progression
Drug Evaluation, Preclinical
Fluorine Radioisotopes
/ pharmacokinetics
Glioma
/ diagnosis
Ligands
Magnetic Resonance Imaging
Male
Positron-Emission Tomography
/ methods
Pyrazoles
/ pharmacokinetics
Pyrimidines
/ pharmacokinetics
Rats
Rats, Wistar
Receptors, GABA-A
/ metabolism
Tumor Cells, Cultured
Cancer imaging
DPA-714
Glioma
Molecular imaging
PET
TSPO
VUIIS1018A
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
6
6
2018
medline:
30
7
2019
entrez:
6
6
2018
Statut:
ppublish
Résumé
There is an urgent need for the development of novel positron emission tomography (PET) tracers for glioma imaging. In this study, we developed a novel PET probe ([ In this study, we synthesized [ Compared to previously reported TSPO tracers including [ These studies illustrate that [
Identifiants
pubmed: 29869061
doi: 10.1007/s11307-018-1198-7
pii: 10.1007/s11307-018-1198-7
pmc: PMC6953265
mid: NIHMS1062387
doi:
Substances chimiques
Carrier Proteins
0
Fluorine Radioisotopes
0
Ligands
0
N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)acetamide
0
Pyrazoles
0
Pyrimidines
0
Receptors, GABA-A
0
Tspo protein, rat
141440-82-6
Fluorine-18
GZ5I74KB8G
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
113-121Subventions
Organisme : NCI NIH HHS
ID : K25 CA127349
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA128323
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA163806
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA126588
Pays : United States
Références
Nat Rev Drug Discov. 2010 Dec;9(12):971-88
pubmed: 21119734
J Nucl Med. 2011 Jan;52(1):107-14
pubmed: 21149488
Mol Pharm. 2011 Jun 6;8(3):823-32
pubmed: 21417480
Mol Imaging Biol. 2014 Dec;16(6):813-20
pubmed: 24845529
Mol Imaging Biol. 2010 Jun;12(3):349-58
pubmed: 19949989
Glia. 2013 Jan;61(1):10-23
pubmed: 22615180
PLoS One. 2015 Oct 30;10(10):e0141659
pubmed: 26517124
J Recept Signal Transduct Res. 2003;23(2-3):225-38
pubmed: 14626449
Eur J Nucl Med Mol Imaging. 2012 May;39(5):811-23
pubmed: 22270507
Cancer Biother Radiopharm. 2013 Apr;28(3):254-9
pubmed: 23350894
J Nucl Med. 2012 Feb;53(2):287-94
pubmed: 22251555
Mol Imaging Biol. 2017 Aug;19(4):578-588
pubmed: 27853987
J Neurosurg. 1989 Jul;71(1):113-8
pubmed: 2544689
Clin Nucl Med. 2011 Feb;36(2):101-8
pubmed: 21220970
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2304-19
pubmed: 18828015
J Med Chem. 2013 Apr 25;56(8):3429-33
pubmed: 23521048
Cancer Res. 1999 Feb 15;59(4):831-42
pubmed: 10029072
Prog Neurobiol. 2006 Dec;80(6):308-22
pubmed: 17156911
J Cereb Blood Flow Metab. 2002 Dec;22(12):1440-52
pubmed: 12468889
Trends Pharmacol Sci. 2006 Aug;27(8):402-9
pubmed: 16822554
Tetrahedron Lett. 2010 Sep 1;51(35):4595-4598
pubmed: 20689673
Brain Res. 2007 Jul 9;1157:100-11
pubmed: 17540348
Lancet Neurol. 2010 Sep;9(9):906-20
pubmed: 20705518
Curr Pharm Des. 2008;14(31):3297-315
pubmed: 19075709
Mol Cancer Res. 2007 Apr;5(4):341-9
pubmed: 17426249
Curr Clin Pharmacol. 2008 Jan;3(1):38-45
pubmed: 18690876
Bioorg Med Chem Lett. 2014 Sep 15;24(18):4466-4471
pubmed: 25172419
Int J Cancer. 2001 Nov 1;94(3):322-7
pubmed: 11745409
Proc Natl Acad Sci U S A. 1987 Feb;84(3):891-5
pubmed: 3027710